Prevalence of Faecal Bacteriophage in Patients With Digestive Symptoms

Evaluation of the Prevalence of Faecal Bacteriophage Carriage in Patients With Digestive Symptoms.

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06524791

Acronym

PREPHAGE

Enrollment

300

Registered

2024-07-29

Start date

2024-11-15

Completion date

2025-11-15

Last updated

2024-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroenteritis

Keywords

bacteriophages

Brief summary

Define the prevalence of fecal phage carriage in individuals with digestive symptoms (i) Determine the concentrations of infectious fecal phages in the stools of individuals with digestive symptoms (detection by culture) (ii) Determine fecal phage genome concentrations in the stools of individuals with digestive symptoms (PCR detection) (iii) Explore factors that could impact fecal phage carriage (patients with digestive symptoms vs. healthy individuals, immunocompromised patients vs. immunocompetent patients)

Interventions

OTHERbacteriophage detection

bacteriophage detection

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Inclusion criteria

* Age between 18 and 60. * Persons having developed gastrointestinal symptoms justifying microbiological stool testing at the time of hospitalization. * Person having received full information on the organization of the research and not having objected to the use of this data

Exclusion criteria

* Persons covered by articles L. 1121-5, L. 1121-7 and L1121-8 of the French Public Health Code. * Pregnant or breast-feeding women, * Minors (not emancipated), * Adult subject to a legal protection measure (guardianship, curatorship, safeguard of justice), * Persons of full age who are unable to give their consent. * Persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care by virtue of articles L. 3212-1 and L. 3213-1.

Design outcomes

Primary

Measure	Time frame	Description
prevalence of faecal phage carriage	baseline	define the prevalence of faecal phage (coliphage) carriage in individuals presenting with digestive symptoms.

Secondary

Measure	Time frame	Description
concentrations of infectious fecal phages	baseline	Determine the concentrations of infectious fecal phages in the stools of individuals with digestive symptoms (detection by culture)
fecal phage genome concentrations	baseline	determine fecal phage genome concentrations in the stools of individuals with digestive symptoms (PCR detection)

Countries

France

Contacts

Primary ContactCédric Hartard

c.hartard@chru-nancy.fr0383153046

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026